MISSISSAUGA, ON, Jan. 31, 2012 /CNW/ - CardioGenics Holdings Inc.
(OTCBB: CGNH), a leading in vitro diagnostics company focused on
cardiology for the point-of-care (POC) market, today announced
financial results and achievements for the year ended October 31, 2011.
"This past year represented significant progress in the commercial
development of our beads business and clinical development of our core
technology, the QL Care Analyzer", said Dr. Yahia Gawad, CEO of
CardioGenics. "We now have two material transfer agreements for our
SAVAsphere magnetic beads, as well as a commercial agreement with Merck
Chimie, who has been testing with a select group of their customers,
for which we expect feedback very soon. Most importantly, we have
advanced the clinical development of the QL Care Analyzer, which now
awaits IRB approval before we move into beta site testing in the first
quarter of this calendar year."
Operational and Financial Highlights (up to and including January 16, 2012)
Announced Submission to IRB for Beta Site Protocol Approval
Commenced Delivery of Beads to Merck Chimie for Select Customer Testing
Created Canadian subsidiary, Luxspheres Inc., to focus on development
and marketing of SAVAsphere™ Magnetic Beads business for use in
Patent's approved for "core technology" of QL Care Analyzer in United
States, Canada, European Union and Japan
Twelve Months Ended October 31, 2011
The Company reported revenues of $8,876 in the twelve months ended
October 31, 2011, compared to zero revenue for the twelve months ended
October 31, 2010. The increase, was the result of the company's first
paramagnetic bead sales in Q4 2011.
Research & Development
Research and development ("R&D") costs were $0.613 million for the
twelve months ended October 31, 2011, compared to $0.605 million for
the twelve months ended October 31, 2010. The increase is mainly
attributable to a staff increase in 2011.
General & Administrative
General and administrative ("G&A") costs, made up of compensation to
officers, occupancy costs, professional fees, listing costs and other
office expenses, was $1.349 million for the twelve months ended October
31, 2011, compared to $1.247 million for the same period in 2010. The
increase in 2011's G&A expenditure was driven primarily by additional
professional and consulting fees.
The Company reported a net loss of $3.900 million ($0.07 per share) in
the twelve months ended October 31, 2011, compared to a net loss of
$2.038 million ($0.04 per share) for the twelve months ended October
For complete financial results, please see our filings at http://www.sec.gov/edgar.shtml.
About CardioGenics Holdings Inc.
Through its operating subsidiaries, the Company develops ultra-sensitive
analyzers and other products targeting the immunoassay segment of the
Point-Of-Care IVD testing market. It has developed the QL Care™
Analyzer, a proprietary and ultra-sensitive Point-Of-Care
immuno-analyzer, which will run a number of diagnostic tests under
development, the first of which will be a series of cardiovascular
diagnostic tests. As part of its core proprietary technology, the
Company has also developed a proprietary method for silver coating
paramagnetic microspheres (a fundamental platform component of
immunoassay equipment), which improve instrument sensitivity to light.
The Company's proprietary microspheres technology and SAVAsphere™ magnetic beads are developed and marketed through the Company's
Luxspheres subsidiary. The Company's principal offices are located in
Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com and www.luxspheres.com.
Safe Harbor Statement - Certain statements made herein that are not
historical are forward-looking within the meaning of the Private
Securities Litigation Reform Act of 1995 and may contain
forward-looking statements, with words such as "anticipate, "believe,"
"expect," "future," "may," "will," "should," "plan," "projected,"
"intend," and similar expressions to identify forward-looking
statements. These statements are based on the Company's beliefs and the
assumptions it made using information currently available to it.
Because these statements reflect the Company's current views concerning
future events, these statements involve risks, uncertainties and
assumptions. The actual results could differ materially from the
results discussed in the forward-looking statements. In any event,
undue reliance should not be placed on any forward-looking statements,
which apply only as of the date of this press release. Accordingly,
reference should be made to the Company's periodic filings with the
Securities and Exchange Commission.
SOURCE CardioGenics Holdings Inc.
For further information: